1.
J Pediatr
; 155(1): 136-9, 2009 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19559299
RESUMO
To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.